Differential gene expression in chicken primary B cells infected ex vivo with attenuated and very virulent strains of infectious bursal disease virus (IBDV).

Katherine L. Dulwich\textsuperscript{1,2*}, Efstathios S. Giotis\textsuperscript{2*}, Alice Gray\textsuperscript{1}, Venugopal Nair\textsuperscript{1}, Michael A. Skinner\textsuperscript{2}, Andrew J. Broadbent\textsuperscript{1#}

\textsuperscript{1}The Pirbright Institute, Ash Road, Woking, GU24 0NF, UK
\textsuperscript{2}Section of Virology, Faculty of Medicine, Imperial College London, St. Mary’s Campus, Norfolk Place, London W2 1PG, UK

*These authors contributed equally to the work
#corresponding author tel: 01483231420, email: andrew.broadbent@pirbright.ac.uk

Key words:
- Infectious bursal disease virus
- Ex vivo primary B cell culture
- Chicken CD40L
- B lymphocytes
- Microarray

Subject category:
1. Animal
   1. RNA viruses

Word count: 6,112

Depository: The original microarray data produced in this study have been deposited in the public database ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/), with the accession number: E-MTAB-5947.
Abstract

Infectious bursal disease virus (IBDV) belongs to the family Birnaviridae and is economically important to the poultry industry worldwide. IBDV infects B cells in the bursa of Fabricius (BF), causing immunosuppression and morbidity in young chickens. In addition to strains that cause classical Gumboro disease, the so-called ‘very virulent’ (vv) strain, also in circulation, causes more severe disease and increased mortality. IBDV has traditionally been controlled through the use of live attenuated vaccines, with attenuation resulting from serial passage in non-lymphoid cells. However, the factors that contribute to the vv or attenuated phenotypes are poorly understood. In order to address this, we aimed to investigate host cell-IBDV interactions using a recently described chicken primary B cell model, where chicken B cells are harvested from the BF and cultured ex vivo in the presence of chicken CD40L. We demonstrated that these cells could support the replication of IBDV when infected ex vivo in the laboratory. Furthermore, we evaluated the gene expression profiles of B cells infected with an attenuated strain (D78) and a very virulent strain (UK661) by microarray. We found that key genes involved in B cell activation and signaling (TNFSF13B, CD72 and GRAP) were down-regulated following infection relative to mock, which we speculate could contribute to IBDV-mediated immunosuppression. Moreover, cells responded to infection by expressing antiviral type I IFNs and IFN-stimulated genes, but the induction was far less pronounced upon infection with UK661, which we speculate could contribute to its virulence.
Introduction

Given the expanding human population, set to reach 9.15 billion by 2050 (1) the global poultry industry is essential to securing enough food for the future. However, immunosuppression has a significant negative impact on the performance of birds (2) and consequently represents a key economic challenge, and a threat to global food security. While environmental stressors and poor nutrition contribute to immunosuppression, many cases in chickens are caused by infection with immunosuppressive viruses, for example infectious bursal disease virus (IBDV) (2).

IBDV is a highly contagious member of the Birnaviridae family that commonly ranks among the top 5 infectious problems of poultry (3). The virus causes an acute disease in chickens known as infectious bursal, or Gumboro, disease (4, 5). Infected birds typically display clinical signs such as ruffled feathers and pale comb/wattles, and they may fail to gain weight. In more severe cases, birds may lack normal social interaction and can be observed with half-shut eyes and drooping wings, as well as signs of weight loss and diarrhoea. In the most severe cases, birds may be solitary and depressed, showing no attempts to feed, and they may have a crop that is filled with water and vent feathers soiled with white faecal material. The virus has a preferred tropism for B cells, the majority of which are located in the bursa of Fabricius (BF), and infection leads to B cell depletion. As a result, birds that survive the infection are typically immunosuppressed, respond less well to vaccination, and are more susceptible to secondary infections, some of which are zoonotic and of Public Health importance. The economic impact of IBDV is therefore two-fold: firstly, due to losses associated with morbidity and mortality and secondly through indirect losses due to immunosuppression (5).

Improving the control of immunosuppressive viruses is a priority for the poultry industry and vaccination is the cornerstone to IBDV control. The use of both inactivated and live attenuated vaccines has been widespread since soon after the identification of IBDV in the
1960s. Next generation vaccines have also been licensed, based on a recombinant herpesvirus of turkey (HVT) vector, or immune complex vaccines (6). However, despite these control efforts, the infection remains endemic worldwide and new strains have emerged and spread, for example immune escape antigenic variants (7, 8) and a pathotypic variant of very virulent (vv) phenotype (9, 10), the latter causing increased severity of disease and higher mortality which can be up to 60% in some flocks, compared to 1-2% following infection with classical strains (5).

The chicken B cell is pivotal to the pathogenesis of IBDV. It is therefore crucial to characterise chicken B cell-virus interactions in order to improve our current understanding of viral pathogenesis and identify areas that can be exploited to develop novel strategies for controlling IBDV. Key questions that remain unanswered are the basis for the increased pathogenicity of the vv strain and the mechanism of attenuation of cell-culture adapted strains. However, until recently, it has not been possible to culture chicken primary B cells ex vivo as, when they are removed from the BF, they do not survive for long (11). Consequently, it has not been possible to perform a thorough analysis of the interactions of chicken B cells with different strains of IBDV, and many pathogenesis studies to date have been conducted in vivo, where birds are infected and bursal tissues are harvested at necropsy for downstream analysis of gene expression (12-17).

The gene encoding chicken CD40 ligand (chCD40L), a molecule responsible for B cell proliferation in vivo, was identified (18) and a soluble fusion protein containing its extracellular domain was subsequently shown to support the proliferation of chicken B cells in culture for up to three weeks (19). In 2015, Schermuly et al. showed that chCD40L-treated B cells could be infected with Marek’s disease virus (11), demonstrating that the cells have the potential for studying the consequences of lymphotropic virus infection. Despite these successes, chicken primary B cell cultures have not yet been applied to the study of IBDV. Here we report the successful culture of chicken primary B cells ex vivo in the presence of
soluble chCD40L and provide data demonstrating that these cells can support the replication
of an attenuated cell-culture adapted strain of IBDV (D78) and a very virulent strain that does
not replicate in non-lymphoid cells (UK661). Furthermore, we characterise the gene
expression profile of B cells infected with both strains of virus, identifying differences that
correlate with pathogenicity.

Results

Chicken primary B cells can be cultured in the presence of chicken CD40L. Consistent
with previous reports (11, 19), we found that when chicken primary B cells were cultured in
the presence of soluble chCD40L, the number and viability of the cells was significantly
increased compared to when cells were cultured in the absence of chCD40L (Fig. 1). The
number of cells increased 4-fold from $9.02 \times 10^5$ to $3.63 \times 10^6$ per ml over a period of 6 days
when chCD40L was added to the culture media, in contrast to when it was absent ($p < 0.05$)
(Fig. 1(a)). Cell viability was also significantly improved, for example from 25% at day 3 post-
culture in the absence of chCD40L to 48% in the presence ($p < 0.05$) (Fig. 1(b)).

Chicken primary B cells can support the replication of both cell-culture adapted and
very virulent strains of IBDV. At 18 hours post-infection, samples of mock and infected cell
cultures were fixed, labelled with a mouse monoclonal antibody against IBDV VP2 and a
goat-anti-mouse secondary antibody labelled with Alexa Fluor 488, and counterstained with
DAPI. Some cells had evidence of green fluorescence around the nucleus (Fig. 2(a)),
consistent with the presence of IBDV in the cytoplastm of infected cells. This was evident for
both D78 and UK661 (Fig. 2(a)). RNA was extracted from infected cultures at 5, 18, 24 and
48 hours post-infection, and subjected to reverse transcription quantitative polymerase chain
reaction (RTqPCR) with primers specific to a conserved region of the IBDV VP4 gene. The
expression of VP4 was first normalised to a house-keeping gene (TBP) and then expressed
as fold change in copy number relative to mock samples in a $\Delta \Delta Ct$ analysis. The average
fold change in IBDV VP4 expression increased to 16,603 copies at 48 hours post-infection
with D78, and 38,632 copies at 48 hours post-infection with UK661. Taken together, these data demonstrate that the chicken primary B cells could support the replication of cell-culture adapted and vv IBDV strains. This is in contrast to primary chicken embryo fibroblasts (CEF) or the immortalised chicken fibroblast cell line, DF-1, which do not support the replication of vv IBDV without prior adaptation that can lead to viral attenuation (20).

**Chicken primary B cells infected with vv UK661 and attenuated D78 show a differential gene expression profile.** Next, we aimed to evaluate how the primary B cells responded to infection with either D78 or UK661. At 5, 18, 24 and 48 hours post-infection, we determined the level of expression of type I IFN (IFNβ) and the interferon stimulated gene (ISG) IFIT5 by RTqPCR. The cells infected with D78 expressed significantly more IFNβ and IFIT5 than cells infected with UK661 at 18, 24 and 48 hours post-infection (**p<0.05, ***p<0.001, ****p<0.0001) (Fig. 3). Moreover, at these time points, the average expression of IFNβ in cells infected with UK661 was actually reduced relative to mock-infected cells, (****p<0.0001 at 18 hours post-infection) (Fig. 3(a)).

To acquire a broader understanding of the effect of infection on the transcriptome, gene expression of mock-, D78- and UK661-infected cultures was screened at 18 hours post-infection using the Affymetrix Chicken Genome array. This array contains comprehensive coverage of 32,773 transcripts corresponding to over 28,000 chicken genes and also includes probe sets for detecting IBDV transcripts, which we used to confirm the virus infection. Full raw and processed microarray data have been deposited in ArrayExpress with the Accession Number E-MTAB-5947. Principal-component analysis (PCA) was used to visualize three-dimensional expression patterns of the RNA data sets (Fig. S1). The samples for each individual treatment (mock-, D78-, and UK661-infected samples) mapped near to each other in a cluster, reflecting minor variations within replicates of each treatment. However, the groups were mapped separately to one another, demonstrating their transcriptomic distinctiveness from one another.
Analysis of the array data showed that 69 genes were differentially regulated, relative to mock-infected cells, following D78 infection (p<0.05, fold change cut-off: 1.5), 12 of which were also those differentially regulated following infection with UK661 (Fig. 4(a)). Of the 69 genes differentially regulated following D78 infection, 53 were up-regulated and 16 were down-regulated. In contrast, all 12 genes differentially regulated following UK661 infection were up-regulated; there were no statistically significant down-regulated genes.

A direct comparison of gene expression between D78 and UK661 infected samples (Table S4) identified 37 differentially regulated genes, 27 of which were up-regulated by D78, relative to UK661 infection, and 10 of which were down-regulated. Two of the D78 versus UK661 up-regulated genes (HBG2 and HSP25), and two of the down-regulated genes (LOC422305 and MCOLN2) were not identified by the comparisons with mock-infected cells.

Unsupervised hierarchical clustering analysis of the significantly differentially regulated genes of the study confirmed that more transcripts were up-regulated following D78-infection compared to UK661-infection (Fig. 4(b)). All the genes could be divided broadly into four similarly-sized groups: The first group included the 16 genes that were transcribed at lower levels in D78-infected samples compared to mock-infected samples. These genes were involved in B-cell activation and signalling (TNFSF13B (which encodes BAFF), CD72, GRAP), immune processes (TLR1LA, DUSP14, PLD4, MDK, PMP2, F10, GSN), and other processes such as protein ubiquitination (UBE2E1) and cholesterol transport and binding (TSPO2). In addition, LOC422305 and MCOLN2, found to be significantly down-regulated in cells infected with D78 relative to cells infected with UK661, were also included in this group, making a total of 18 genes. The LOC422305 gene encodes the mitochondrial-like ES1 protein (21), and the MCOLN2 gene encodes the ion channel TRPML2 (22) that has been reported to enhance the replication of yellow fever and dengue viruses (23, 24). The other three groups comprised the 53 genes that were transcribed to a higher level in D78-infected cells relative to mock-infected cells, as well as the two genes that were significantly up-
regulated by infection with D78 relative to infection with UK661 (HBG2 and HSP25), making a total of 55 genes. These were further sub-grouped on the basis of their expression in cells infected with UK661, with their transcripts being present at: a similar level (19 genes), a marginally higher level (17 genes) or a moderately higher level (19 genes) than in mock-infected cells. Most of the genes in these groups were involved in innate immune responses (IFI6, SAMD9L, NMI, IRF7, LGP2, IFI35, HMOX1, LY96, SOCS1, and others), antiviral responses (OASL, Mx1, IFIT5, RSAD2, IFIH1, IRF1, EIF2AK2 or PKR, TRIM25, IRF7, PMAIP1, LGP2, DDX60 and PML), TGFβ signalling (DACT2, PML), inflammation (CCL4, CCL5) and apoptosis (PMAIP1, PML). Previous reports have also shown that members of several virus families modulate HSP25 expression in a variety of cell types suggesting it has a broad role (25).

Enrichment analysis was performed using MetaCore (Clarivate) by matching differentially regulated genes in functional Gene Ontologies (GO) and biological processes. The probability of a random intersection between a set of genes with ontology processes was estimated with the “P” value of the hypergeometric intersection (See Fig. S2-S4 for a more detailed analysis). The top GO processes were “defence response to virus” and “immune system processes” (Fig. 4(c)). Taken together, these data show that following IBDV infection cells launch a type I IFN response, characterised by the induction of ISGs, but that the response is more marked following D78-infection than UK661-infection. One limitation of the enrichment analysis is that it relied on a comparison with mammalian gene counterparts. Previously, we have defined chicken ISGs by using DNA microarrays and RNA sequencing in CEFs stimulated with recombinant chicken IFNα (26), and we have made the full list of chicken ISGs publicly available at http://cisbic.bioinformatics.ic.ac.uk/skinner. To confirm and extend the enrichment analysis observations, we compared the relative expression of known chicken ISGs between cells infected with the two virus strains. While the core set of virus-induced genes was similar, the magnitude of the change in gene expression was lower
in cells infected with UK661 than in cells infected with D78. Moreover, RSAD2, TGM2 and
DDX60 were not induced by UK661-infection (Fig. 4(d)).

Confirmation of microarray data for selected genes by real-time RT-PCR.
The microarray results were validated by determining the level of expression of a panel of
genes (IFIT5, IFI6, OASL, Mx1, RSAD2, IFIH1, IFNα and IFNβ) by RTqPCR (Fig. 5). For
this analysis, the log_{10} of the fold changes by microarray and RTqPCR were plotted
against one another and the Spearman rank correlation calculated. The mean Spearman
correlation coefficient (Spearman’s ρ) of cDNA microarray versus qPCR was 0.90.
Therefore, the level of differential gene expression detected by each platform was highly
similar.

Taken together, our data show that chicken primary B cells, cultured ex vivo in the
presence of chCD40L, can support the replication of cell-culture adapted and vv strains of
IBDV. We identified several genes involved in B cell activation and signalling that were
down-regulated following D78 infection, including TNFSF13B (the gene encoding BAFF),
CD72 and GRAP. The cells responded to the infection by inducing a type I IFN response
with the up-regulation of ISGs, however, the magnitude of the response was considerably
lower in cells infected with the vv strain UK661 than in cells infected with the attenuated
strain D78.

Discussion
Despite decades of vaccination, IBDV continues to be endemic world-wide and frequently
ranks in the top 5 diseases of poultry (3). Vaccines fail to induce sterilising immunity, and
vaccinated birds may continue to shed wild-type strains and reassortant viruses that contain
genome segments from vaccine and field strains (27, 28). Moreover, antigenically variant
viruses have emerged on several occasions, necessitating the development of novel
vaccines (7, 8) and a pathotypic variant, the very virulent strain, emerged in the late 1980s
(apparently by reassortment) to spread across the globe, often necessitating the use of less attenuated vaccines (6, 9, 10). Even in the absence of overt clinical signs, immunosuppression caused by IBDV infection can be an underlying cause of increased susceptibility to secondary infections, some of which can be zoonotic. For example, pre-exposure of chickens to IBDV exacerbated the pathology, persistence, or shedding of *Salmonella enteritidis, Campylobacter jejuni* and *Escherichia coli* (29-31), and a recent case-control study in Pakistan identified a history of IBDV infection in flocks as a significant risk factor associated with avian influenza virus (AIV) infection in chickens (32). Moreover, experimental inoculation with IBDV prolonged the shedding of a subsequent AIV challenge (33), and it was possible to adapt a mallard H5N2 AIV to chickens by serial passage in birds that had previously been inoculated with IBDV, but not in birds that lacked IBDV exposure (34).

Improved control strategies are therefore needed and, in the future, it may be possible to breed or engineer chickens that are resistant to IBDV disease, immunosuppression or even infection, but key scientific questions need to be answered before progress can be made in these areas. IBDV has a preferred tropism for B cells, and it is crucial to develop a greater understanding of the molecular interactions of IBDV with this cell type. The majority of B cells are located in the BF and *in vivo* studies have shown that, following IBDV infection, there is an increase in the expression of genes involved in pro-inflammatory cytokine responses, type I IFN induction and signalling as well as apoptosis in the BF (12, 16, 17). However, the BF is made up multiple cell types and, following infection, there is an influx of inflammatory cells and effector T cells into the organ. The various cell populations differ in the profile of genes they express, for example elevated expression of CD3, IL-18R1 and iNOS have been attributed to an influx of T cells, NK cells and macrophages, respectively (16). It is therefore difficult to interpret how the infected B cells respond to IBDV. To address this, some research groups have characterised the transcriptional response of cells infected with IBDV in culture (35-39). These studies have the advantage of well-defined multiplicities...
of infection (MOIs) and time points post-infection, and as transcriptional responses are from one cell population, they are not confounded by multiple cell-types found in vivo. However, until recently, it was not possible to culture chicken primary B cells ex vivo, so the transcriptome has typically been characterised in either fibroblast cells (35, 36, 39) or dendritic cells (37). While providing some insight into host cell-IBDV interactions, vv IBDV strains will not replicate in fibroblast cells without prior adaptation and, as infection of B cells is crucial to the pathogenesis of IBDV, the relevance of the data should not be over-interpreted. Only one study to date has characterised the transcriptional response of B cells to IBDV infection (38), however that study utilised an immortalised B cell line that had been transformed following infection with ALV (DT40 cells), limiting the conclusions that can be made.

In this study, we describe the successful culture of chicken primary B cells ex vivo in the presence of soluble chCD40L and demonstrate that these cells can support the replication of an attenuated strain and the prototypic vv strain of IBDV. This ex vivo model of IBDV infection allows us to study the interactions of the virus with its relevant host cell, retaining the advantages of in vivo studies without the limitations of multiple cell-types that might confound the data. Moreover, our model permits the use of defined MOIs and time-points, thus retaining the advantages of in vitro systems. We have extended this work by describing, for the first time, the transcriptional profile of chicken primary B cells infected with IBDV. While the validity of the model in recapitulating in vivo data should be evaluated experimentally, the gene expression profile we have observed is consistent with that reported in previous studies. Thus 35 of the genes that we identified as being differentially expressed in D78-infected cells compared to mock-infected cells were previously reported as differentially expressed following IBDV infection in vivo (12, 14-17). Only one contradiction was found: the GSN gene was found to be down-regulated in our study, yet up-regulated in one in vivo study (17). GSN encodes Gelsolin, which regulates actin assembly and has also been associated with inhibiting apoptosis (40). The reason for this discrepancy
is unknown; it could be because our experiment characterised gene expression at 18 hours post-infection, whereas the *in vivo* study was conducted at 3 and 4 days post infection.

We demonstrated that IBDV infection led to the down-regulation of key genes involved in B cell activation and signaling, such as TNFSF13B, CD72 and GRAP. This is consistent with previous *in vivo* studies that showed down-regulation of TNFSF13B, CD72 and GRAP in bursal tissue following infection with IBDV strain F52/70 (16, 17), and with an *in vitro* study that found CD72 to be down-regulated following IBDV infection of DT40 cells (38).

TNFSF13B encodes the B cell activating factor (BAFF), which is essential for the survival of B cells. BAFF is a transmembrane protein that is readily cleaved to release a soluble factor. There are three known receptors for BAFF that are expressed on B cells in varying amounts related to the maturation of the cell, and BAFF-induced signaling stimulates B cells to undergo proliferation and counters apoptosis (41). CD72 is a co-receptor on B cells, the expression of which is enhanced by BAFF (42). It contains two immunoreceptor tyrosine-based inhibitory motifs (ITIMs), ITIM1 and ITIM2, and studies have associated it with both positive and negative signaling (43). Ligation of CD72 has been shown to induce the proliferation of both resting and activated B cells, with positive signaling thought to be mediated via the Grb2-Sos-Ras pathway (43). Grb2 and the Grb2-related adaptor protein (GRAP) are both members of the same family of adapter proteins that couple signals from receptor tyrosine kinases to the Ras pathway (44). Moreover, in the chicken DT40 B-cell line, the Grb2 protein has been shown to interact with the ITIM2 motif of the avian CD72 homologue, attenuating negative signals from the ITIM1 motif, thus permitting positive signaling (45). We speculate that, as BAFF leads to the up-regulation of CD72, which positively signals via Grb-2 like proteins, the combination of BAFF, CD72 and GRAP leads to B cell activation and proliferation. As all three proteins are down-regulated following IBDV infection, it is tempting to conclude that IBDV targets this pathway, thereby reducing B cell activation and proliferation, and that this could contribute to the immunosuppression observed during infection, although this requires experimental confirmation.
We demonstrated that chicken primary B cells responded to infection with D78 by up-regulating the expression of type I IFN genes and ISGs. This is consistent with a study by Hui et al, which characterised the gene expression of DF-1 cells infected with the D78 strain (35). Twenty two of the genes that we identified as being differentially expressed in D78-infected chicken primary B cells were similarly differentially expressed following D78-infection of DF-1 cells. Notably, Hui et al identified that D78 triggered an IFIT5-IRF1/3-Viperin pathway in infected DF-1 cells (35). In our study, D78 infection also led to the significant up-regulation of IFIT5, IRF1, IRF7 and RSAD2 (Viperin), suggesting that this pathway is also triggered in chicken primary B cells infected with D78. In contrast, this pathway did not appear to be induced by infection with UK661.

We also found that B cells infected with the attenuated strain of IBDV (D78) up-regulated the expression of genes involved in the innate immune response to a significantly greater extent than cells infected with the vv strain (UK661). Previous work using RTqPCR also showed the expression of type I IFNα and β to be significantly lower in BF tissue taken from birds infected with UK661 than with a classical strain, F52-70 (46). However, the authors studied each virus in separate experiments and inoculated birds with different titres of the two strains, limiting the conclusions that could be made. In contrast, we characterised responses in cells infected at the same time with the same MOI of the two strains. Moreover, we found that IFNβ expression was significantly reduced in cells infected with UK661 compared to mock infected cells. This suggests that UK661 is not only able to inhibit the up-regulation of type I IFN, but might actually suppress its induction. Taken together, our results imply that UK661 is able to inhibit the up-regulation of antiviral responses to a greater extent than D78, which we speculate could contribute to its enhanced virulence. To date, two components of IBDV, VP3 and VP4, have been implicated in the suppression of innate immune responses to IBDV infection. The VP3 protein binds the viral double-stranded (ds) RNA genome and is thought to block the interaction of MDA5 with the dsRNA, thereby inhibiting downstream events that culminate in type I IFN production (47). In addition, the VP4 protein binds to the
cellular glucocorticoid-induced leucine zipper (GILZ) protein, which inhibits the activation of nuclear factor kappa enhancing binding (NF-KB) protein and activator protein-1 (AP-1) (48).

In mammalian cells, NF-KB and AP-1 co-operate with interferon regulatory factor (IRF) 3 and 7 to stimulate type I IFN transcription. IBDV VP4 may therefore inhibit type I IFN responses via binding to and enhancing the inhibitory action of GILZ (48). It is possible that differences in the sequences of these viral proteins between D78 and UK661 lead to differences in the antagonism of type I IFN induction.

In conclusion, the application of soluble chCD40L has opened up the possibility of studying viral pathogenesis in chicken primary B cells. While cells treated in this way have previously been used in the study of the Marek’s disease herpesvirus, this represents the first study applying them to the study of IBDV-host cell interactions. Our data illustrate interesting differences between how attenuated and very virulent strains behave in infected B cells that could shed light on both the molecular basis of IBDV-mediated immunosuppression, and on the basis of the enhanced virulence of the vv strain.

Methods

Immortalised cell culture and virus

DT40 cells (49) were maintained in RPMI media supplemented with L-glutamine and sodium bicarbonate (Sigma-Aldrich), 10% heat-inactivated foetal bovine serum (FBS) (Sigma-Aldrich), tryptose phosphate broth (Sigma-Aldrich), sodium pyruvate (Sigma-Aldrich), and 50mM beta-mercaptoethanol (Gibco). HEK-293T cells stably expressing a soluble chicken CD40L construct, msCD8-CD40L (18), were cultured in RPMI supplemented with L-glutamine, sodium bicarbonate, 10% heat-inactivated FBS, and 1ug/ml puromycin (Gibco). Immortalised cells were cultured at 37°C and 5% CO₂. A cell-culture adapted attenuated strain, D78 (8), and a vv strain, UK661 (9, 10), of IBDV were kind gifts from Dr Nicolas Eterradossi, ANSES, France.
Virus titration

Ten-fold serial dilutions of D78 and UK661 viruses were added to DT40 cells in 96 well-plates and incubated for 3 days, whereupon cultures were fixed with 4% paraformaldehyde and labelled with a mouse monoclonal antibody against IBDV VP2 (clone JF7-PD5; Kim Wark PhD Thesis, University of Hertfordshire, 2000; M. A. Skinner, unpublished) and a goat-anti-mouse monoclonal antibody conjugated to Alexa Fluor® 488 (Thermo Fisher Scientific).

Cultures were scored as positive or negative based on the presence or absence of green fluorescent cells and the dilution at which 50% of the cells were infected (the tissue culture infectious dose 50, TCID$_{50}$) was computed using the method described by Reed and Muench (50).

CD40L stock production

Supernatant was harvested from HEK-293T cells stably expressing the msCD8-CD40L construct (chicken (ch) CD40L) and concentrated using Pierce$^\text{TM}$ Protein Concentrators PES (Thermo Fisher Scientific) according to the manufacturer’s instructions. Concentrated chCD40L was filter sterilised using a 0.22µM Millex-GP Syringe Filter (Merck), stored at 4°C and titrated prior to use. Briefly, primary B cells were cultured in the presence of two-fold serial dilutions of chCD40L for up to 6 days. Each day, the number and viability of the cells was determined by Trypan Blue (Sigma-Aldrich) exclusion and the chCD40L dilution which gave the most favourable number and viability was selected for use (1:40).

Chickens

Embryonated eggs of the Rhode Island Red line were provided by the National Avian Research Facility (NARF). Chickens were hatched and housed in specific pathogen free (SPF) facilities at The Pirbright Institute and reared until 3 weeks of age, whereupon they were humanely culled by a schedule 1 procedure. All procedures were performed in accordance with the UK Animal (Scientific Procedures) Act 1986 under Home Office
Establishment, Personal and Project licences, after the approval of the internal animal welfare and ethical review board (AWERB).

**Chicken primary B cell culture**

The bursa of Fabricius was harvested aseptically post mortem and washed in sterile PBS. An enzyme solution containing 2.2mg/ml collagenase D (Sigma-Aldrich) in Hanks Balanced Salt Solution supplemented with calcium (Gibco) and 7.5% sodium carbonate was used to digest the bursal tissue. Once digested the tissue was passed through a 100µM Falcon™ cell strainer (Thermo Fisher Scientific) into cell medium containing Hanks Balanced Salt Solution (Gibco) supplemented with 7.5% sodium carbonate and 500mM EDTA (Sigma-Aldrich), before pelleting. Cells were resuspended in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with FBS, chicken serum (Sigma-Aldrich), insulin transferrin selenium (Gibco), beta-mercaptoethanol (Gibco), and penicillin/streptomycin and nystatin (B cell media; as described by (19)) before undergoing centrifugation at 2,000rpm for 20 minutes at 4°C over Histopaque 1083 (Sigma-Aldrich). Bursal cells that banded at the interface of the medium and histopaque were collected, washed in PBS and counted using the TC20™ Automated Cell Counter (Bio-Rad). Cells were seeded in 24 well plates at 1x10^7 cells per ml and maintained at 37°C in 5% CO₂ in B cell media supplemented with chCD40L.

**Virus inoculation**

Chicken primary B cells were infected with the attenuated strain D78 and the vv strain UK661 at a MOI of 3, after which cells were washed with media and cultured in B cell media supplemented with chCD40L. Following incubation at 37°C with 5% CO₂ for the indicated amount of time, a 100µl sample of each well was obtained for processing for bioimaging. The remaining cells were washed in PBS, resuspended in RLT buffer and stored at -80°C until nucleic acid extraction.
Bioimaging

Cells were pelleted, washed in PBS, and fixed in 4% paraformaldehyde (Sigma-Aldrich) for 1 hour at room temperature. Cells were permeabilised using 0.5% Triton X-100 (Sigma-Aldrich) for 30 minutes at room temperature, blocked with 4% bovine serum albumin (Sigma-Aldrich) for 30 minutes at room temperature on a rotating platform and then labelled with a primary mouse monoclonal antibody against the IBDV VP2 protein (clone JF7-PD5) and incubated for 1 hour at room temperature. After washing in PBS, the cells were incubated for 1 hour with a goat-anti-mouse secondary monoclonal antibody conjugated to Alexa Fluor® 488 (Thermo Fisher Scientific). Cells were counterstained with DAPI (Sigma-Aldrich) and adhered to glass cover slips (TAAB, Aldermaston, UK) that had been coated with CellTak (Fisher Scientific) by centrifugation. Cover slips were mounted onto glass slides and stained cells were viewed with a Leica SP5 confocal microscope.

Nucleic acid extraction

Total RNA was extracted from mock-infected and IBDV-infected B cells using an RNeasy kit (Qiagen) according to the manufacturer’s instructions. On-column DNA digestion was performed using RNase-free DNase (Qiagen) to remove contaminating genomic DNA. RNA samples were quantified using a Nanodrop Spectrophotometer (Thermo Scientific) and checked for quality using a 2100 Bioanalyzer (Agilent Technologies). All RNA samples had an RNA integrity number (RIN) ≥ 9.6. RNA samples were halved and processed for either microarrays or RTqPCR.

Quantification of virus replication by RTqPCR

Reverse transcription of RNA samples was performed using SuperScript™ III Reverse Transcriptase (Thermo Fisher Scientific). The cDNA was synthesised according to the manufacturer’s instructions. Forward and reverse primers and a Taqman probe (Table S1) targeting a conserved region of the IBDV VP4 sequence (Sigma-Aldrich) were used to amplify the template. Briefly, the template, primers and probe were added to a Taqman
Universal PCR Master Mix (Applied Biosystems) and reactions were performed on 7500 Fast Real-Time PCR system (Life Technologies) using the following cycling conditions: 95°C for 10 minutes; 40 cycles of 95°C for 15 seconds, 60°C for 1 minute; 95°C for 15 seconds; 60°C for 1 minute; 95°C for 30 seconds; 60°C for 15 seconds. All target gene expression levels were normalised to the housekeeping gene TBP and compared with the mock controls using the comparative Ct method (also referred to as the 2^-ΔΔCT method) (51).

**Microarrays**

For the microarray study the GeneChip® 3´ IVT Express Kit (Affymetrix) was used following the manufacturer’s instructions. Hybridisation of RNA to chips and scanning of arrays was performed by the Medical Research Council’s Clinical Sciences Centre (CSC) Genomics Laboratory, Hammersmith Hospital, London, UK. RNA was hybridised to GeneChip Chicken Genome Array chips (Affymetrix) in a GeneChip Hybridization Oven (Affymetrix), the chips were stained and washed on a GeneChip Fluidics Station 450 (Affymetrix), and the arrays were scanned in a GeneChip Scanner 3000 7G with autoloader (Affymetrix).

**Nucleic acid labelling**

Biotinylated fragmented RNA was prepared for each sample using standard procedures in GeneChip ® 3´ IVT Express Kit User’s manual.

**Nucleic acid hybridization to array**

Array hybridisation was performed according to the manufacturer’s instructions (Affymetrix). Labelled samples were hybridized to the GeneChip Chicken Genome Arrays (Affymetrix Inc.) in a GeneChip Hybridization Oven for 16 h at 45°C and 60 rpm in an Affymetrix Hybridization Oven 645.
Array scanning and feature extraction protocol

After washing and staining, the arrays were scanned with the Affymetrix GeneChip Scanner 3000 7G. Gene-level expression signal estimates were derived from CEL files generated from raw data using the multi-array analysis (RMA) algorithm implemented from the Affymetrix GeneChip Command Console Software Version 3.0.1.

Normalisation data transformation protocol

Data pre-processing and filtering was done using the Partek Genomics Suite software, v.6.6 and included: RMA background correction, quantile normalisation across all chips in the experiment, log₂ transformation and median polish summarisation.

Microarray data analysis

A one-way ANOVA (variable: treatment) adjusted with the Benjamini–Hochberg multiple-testing correction (false discovery rate (FDR) of $P<0.05$) was performed with Partek Genomics Suite (v6.6, Partek) across all samples. Principal component analysis (PCA) which shows sample variability in three-dimensional space confirmed lack of variability within infected samples (Fig. S1). Comparisons were conducted between B-cells infected with D78 and UK661 versus mock-treated cells and between cells infected with D78 versus cells infected with UK661. The analysis cut off criteria were fold change $\geq 1.5$ and $P$-value $\leq 0.05$. The Affymetrix chicken genome arrays contain probe sets for detecting transcripts from 17 avian viruses, including IBDV, allowing confirmation of viral infection. The full results of the microarray analysis are listed in Tables S2-S4. According to the MIAME guidelines, the original microarray data produced in this study have been deposited in the public database ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/), with the accession number: E-MTAB-5947.

Data mining and enrichment analysis was performed using the MetaCore software suite (Clarivate Analytics, https://clarivate.com/products/metacore/). Enrichment analysis
consisted of mapping gene IDs of the datasets onto gene IDs of human orthologues in entities of built-in functional ontologies represented in MetaCore by pathway maps and process networks. Statistical significance was measured by the number of genes that map onto a given pathway and was calculated on the basis of p-value, based on hypergeometric distribution (a built-in feature of MetaCore). Enrichment analysis for the mock-infected Vs D78, mock-infected Vs UK661 and D78 Vs UK661 datasets is presented in Fig. S2-S4.

Microarray validation
RTqPCR was performed on RNA samples using a two-step procedure. RNA was first reverse-transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions. qPCR was then conducted on the cDNA in a 384-well plate with a ABI-7900HT Fast qPCR system (Applied Biosystems). Mesa Green qPCR MasterMix (Eurogentec) was added to the cDNA (5μl for every 2μl of cDNA). The following amplification conditions were used: 95°C for 5 minutes; 40 cycles of 95°C for 15 seconds, 57°C for 20 seconds, and 72°C for 20 seconds; 95°C for 15 seconds; 60°C for 15 seconds; and 95°C for 15 seconds. Primer sequences for genes that were used in the study are given in Supplementary Table 1. The output Ct values and dissociation curves were analysed using SDS v2.3 and RQ Manager v1.2 (Applied Biosystems). Gene expression data were normalised against the housekeeping gene GAPDH, and compared with the mock controls using the comparative C_T method (51). All samples were loaded in triplicate.

Funding information
AB is funded through the UK’s Biotechnology and Biosciences Research Council (BBSRC) via grant BBS/E/I/00001845 (“Fellowship in IBDV Research”). VN, MAS and ESG are funded through the BBSRC via grant BB/K002465/1 (“Developing Rapid Responses to Emerging Virus Infections of Poultry (DRREVIP)”).
Acknowledgements

We are grateful for the skilled support of Laurence Game and Ivan Andrew of the Medical Research Council's (MRC) Clinical Sciences Centre's (CSC) Genomics Laboratory in conducting microarray analysis. In addition, we thank Nicolas Eterradossi of ANSES France for supplying IBDV strains, and for useful discussions.

Conflict of interest

We declare no conflicts of interest

Ethical statement

All animal procedures were performed in accordance with the UK Animal (Scientific Procedures) Act 1986 under Home Office Establishment, Personal and Project licences, after the approval of the Animal Welfare and Ethical Review Body (AWERB) at The Pirbright Institute.

References

1. Thornton PK. Livestock production: recent trends, future prospects. Philos Trans R Soc Lond B Biol Sci. 2010;365(1554):2853-67.
2. Hoerr FJ. Clinical aspects of immunosuppression in poultry. Avian Dis. 2010;54(1):2-15.
3. Cazaban C, Gardin Y, Oort Rv. Gumboro Disease- A persisting Problem. CEVA, 2017.
4. Ingrao F, Rauw F, Lambrecht B, van den Berg T. Infectious Bursal Disease: a complex host-pathogen interaction. Dev Comp Immunol. 2013;41(3):429-38.
5. van den Berg TP, Eterradossi N, Toquin D, Meulemans G. Infectious bursal disease (Gumboro disease). Rev Sci Tech. 2000;19(2):509-43.
6. Muller H, Mundt E, Eterradossi N, Islam MR. Current status of vaccines against infectious bursal disease. Avian Pathol. 2012;41(2):133-9.
7. Heine HG, Haritou M, Failla P, Fahey K, Azad A. Sequence analysis and expression of the host-protective immunogen VP2 of a variant strain of infectious bursal disease virus which can circumvent vaccination with standard type I strains. J Gen Virol. 1991;72 ( Pt 8):1835-43.
8. Snyder DB, Lana DP, Savage PK, Yancey FS, Mengel SA, Marquardt WW. Differentiation of infectious bursal disease viruses directly from infected tissues with neutralizing monoclonal antibodies: evidence of a major antigenic shift in recent field isolates. Avian Dis. 1988;32(3):535-9.
9. Brown MD, Green P, Skinner MA. VP2 sequences of recent European 'very virulent' isolates of infectious bursal disease virus are closely related to each other but are distinct from those of 'classical' strains. J Gen Virol. 1994;75 ( Pt 3):675-80.
10. Brown MD, Skinner MA. Coding sequences of both genome segments of a European 'very virulent' infectious bursal disease virus. Virus Res. 1996;40(1):1-15.
11. Schermuly J, Greco A, Hartle S, Osterrieder N, Kaufer BB, Kaspers B. In vitro model for lytic replication, latency, and transformation of an oncogenic alphaherpesvirus. Proc Natl Acad Sci U S A. 2015;112(23):7279-84.

12. Guo X, Wang L, Cui D, Ruan W, Liu F, Li H. Differential expression of the Toll-like receptor pathway and related genes of chicken bursa after experimental infection with infectious bursa disease virus. Arch Virol. 2012;157(11):2189-99.

13. He X, Chen Y, Kang S, Chen G, Wei P. Differential Regulation of chTLR3 by Infectious Bursal Disease Viruses with Different Virulence In Vitro and In Vivo. Viral Immunol. 2017.

14. Ou C, Wang Q, Zhang Y, Kong W, Zhang S, Yu Y, et al. Transcription profiles of the responses of chicken bursae of Fabricius to IBDV in different timing phases. Virol J. 2017;14(1):93.

15. Rasoli M, Yeap SK, Tan SW, Roohani K, Kristeen-Teo YW, Altheen NB, et al. Differential modulation of immune response and cytokine profiles in the bursae and spleen of chickens infected with very virulent infectious bursal disease virus. BMC Vet Res. 2015;11:75.

16. Ruby T, Whittaker C, Withers DR, Chelbi-Alix MK, Morin V, Oudin A, et al. Transcriptional profiling reveals a possible role for the timing of the inflammatory response in determining susceptibility to a viral infection. J Virol. 2006;80(18):9207-16.

17. Smith J, Sadeyen JR, Butter C, Kaiser P, Burt DW. Analysis of the early immune response to infection by infectious bursal disease virus in chickens differing in their resistance to the disease. J Virol. 2015;89(5):2469-82.

18. Tregaskes CA, Glansbeek HL, Gill AC, Hunt LG, Burnside J, Young JR. Conservation of biological properties of the CD40 ligand, CD154 in a non-mammalian vertebrate. Dev Comp Immunol. 2005;29(4):361-74.

19. Kothlow S, Morgenroth I, Tregaskes CA, Kasanga CJ, Maw MT, Ohya K, Yamaguchi T, et al. Chicken B lymphoma DT40 cells as a useful tool for in vitro analysis of pathogenic infectious bursal disease virus. J Vet Med Sci. 2008;70(4):407-10.

20. Terasaki K, Hirayama H, Kasanga CJ, Maw MT, Ohya K, Yamaguchi T, et al. CD40 ligand supports the long-term maintenance and differentiation of chicken B cells in culture. Dev Comp Immunol. 2008;32(9):1015-26.

21. Masuda T, Wada Y, Kawamura S. ES1 is a mitochondrial enlarging factor contributing to form mega-mitochondria in zebrafish cones. Sci Rep. 2016;6:22360.

22. Sun L, Hua Y, Vergarajauregui S, Diab HI, Puertollano R. Novel Role of TRPML2 in the Regulation of the Innate Immune Response. J Immunol. 2015;195(10):4922-32.

23. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2011;1(6):519-25.

24. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481-5.

25. Li L, Sevinsky JR, Rowland MD, Bundy JL, Stephenson JL, Sherry B. Proteomic analysis reveals virus-specific Hsp25 modulation in cardiac myocytes. J Proteome Res. 2010;9(5):2460-71.

26. Giotis ES, Robey RC, Skinner NG, Tomlinson CD, Goodbourn S, Skinner MA. Chicken interferome: avian interferon-stimulated genes identified by microarray and RNA-seq of primary chick embryo fibroblasts treated with a chicken type I interferon (IFN-alpha). Vet Res. 2016;47(1):75.

27. Cui P, Ma SJ, Zhang YG, Li XS, Gao XY, Cui BA, et al. Genomic sequence analysis of a new reassortant infectious bursal disease virus from commercial broiler flocks in Central China. Arch Virol. 2013;158(9):1973-8.

28. Kasanga CJ, Yamaguchi T, Munang'andu HM, Ohya K, Fukushima H. Genomic sequence of an infectious bursal disease virus isolate from Zambia: classical attenuated segment B reassortment in nature with existing very virulent segment A. Arch Virol. 2013;158(3):685-9.

29. Kurukulsuriya S, Ahmed KA, Ojkic D, Gunawardana T, Gupta A, Goonewardene K, et al. Circulating strains of variant infectious bursal disease virus may pose a challenge for antibiotic-free chicken farming in Canada. Res Vet Sci. 2016;108:54-9.
30. Phillips RA, Opitz HM. Pathogenicity and persistence of Salmonella enteritidis and egg contamination in normal and infectious bursal disease virus-infected leghorn chicks. Avian Dis. 1995;39(4):778-87.
31. Subler KA, Mickaël CS, Jackwood DJ. Infectious bursal disease virus-induced immunosuppression exacerbates Campylobacter jejuni colonization and shedding in chickens. Avian Dis. 2006;50(2):179-84.
32. Chaudhry M, Rashid HB, Thrusfield M, Welburn S, Bronsvoort BM. A case-control study to identify risk factors associated with avian influenza subtype H9N2 on commercial poultry farms in Pakistan. PLoS One. 2015;10(3):e0119019.
33. Motamed N, Mayahi M, Seifi MR, Jafari RA. Effect of infectious bursal disease virus on pathogenicity of avian influenza virus subtype H9N2 in broiler chicks. Journal of Veterinary Medicine and Animal Health. 2013;5(10).
34. Ramirez-Nieto G, Shivaprasad HL, Kim CH, Lillegard HS, Song H, Osorio IG, et al. Adaptation of a mallard HSN2 low pathogenicity influenza virus in chickens with prior history of infection with infectious bursal disease virus. Avian Dis. 2010;54(1 Suppl):513-21.
35. Hui RK, Leung FC. Differential Expression Profile of Chicken Embryo Fibroblast DF-1 Cells Infected with Cell-Adapted Infectious Bursal Disease Virus. PLoS One. 2015;10(6):e0111771.
36. Li YP, Handberg KJ, Juul-Madsen HR, Zhang MF, Jorgensen PH. Transcriptional profiles of chicken embryo cell cultures following infection with infectious bursal disease virus. Arch Virol. 2007;152(3):463-78.
37. Lin J, Xia J, Zhang K, Yang Q. Genome-wide profiling of chicken dendritic cell response to infectious bursal disease. BMC Genomics. 2016;17(1):878.
38. Quan R, Zhu S, Wei L, Wang J, Yan X, Li Z, et al. Transcriptional profiles in bursal B-lymphoid DT40 cells infected with very virulent infectious bursal disease virus. Virol J. 2017;14(1):7.
39. Wong RT, Hon CC, Zeng F, Leung FC. Screening of differentially expressed transcripts in infectious bursal disease virus-induced apoptotic chicken embryonic fibroblasts by using cDNA microarrays. J Gen Virol. 2007;88(Pt 6):1785-96.
40. Garcia-Bartolome A, Penas A, Marin-Buera L, Lobo-Jarne T, Perez-Perez R, Moran M, et al. Respiratory chain enzyme deficiency induces mitochondrial location of actin-binding Gelsolin to modulate the oligomerization of VDAC complexes and cell survival. Hum Mol Genet. 2017.
41. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465-75.
42. Lyu M, Hao Y, Li Y, Lyu C, Liu W, Li H, et al. Upregulation of CD72 expression on CD19+ CD27+ memory B cells by CD40L in primary immune thrombocytopenia. Br J Haematol. 2017;178(2):308-18.
43. Wu HJ, Bondada S. CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. J Clin Immunol. 2009;29(1):12-21.
44. Feng GS, Ouyang YB, Hu DP, Shi ZQ, Gentz R, Ni J. Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. J Biol Chem. 1996;271(21):12129-32.
45. Fujiwara N, Hidano S, Mamada H, Ogasawara K, Kitamura D, Cooper MD, et al. A novel avian homologue of CD72, chB1r, down modulates BCR-mediated activation signals. Int Immunol. 2006;18(5):775-83.
46. Eldaghayes I, Rothwell L, Williams A, Withers D, Balu S, Davison F, et al. Infectious bursal disease virus: strains that differ in virulence differentially modulate the innate immune response to infection in the chicken bursa. Viral Immunol. 2006;19(1):83-91.
47. Ye C, Jia L, Sun Y, Hu B, Wang L, Lu X, et al. Inhibition of antiviral innate immunity by birnavirus VP3 protein via blockage of viral double-stranded RNA binding to the host cytoplasmic RNA detector MDA5. J Virol. 2014;88(19):11154-65.
48. Li Z, Wang Y, Li X, Li X, Cao H, Zheng SJ. Critical roles of glucocorticoid-induced leucine zipper in infectious bursal disease virus (IBDV)-induced suppression of type I Interferon expression and enhancement of IBDV growth in host cells via interaction with VP4. J Virol. 2013;87(2):1221-31.
49. Baba TW, Giroir BP, Humphries EH. Cell lines derived from avian lymphomas exhibit two distinct phenotypes. Virology. 1985;144(1):139-51.

50. Reed R, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:494-7.

51. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8.
Figure Legends

Figure 1. Chicken primary B cells can be cultured in the presence of chicken CD40L. Chicken primary B cells were cultured in the presence (black bars) or absence (white bars) of chicken (ch)CD40L and the number of live cells (A) and the percentage of viable cells (B) determined at the indicated time-points post infection. Data shown are representative of at least three replicate experiments, error bars represent the standard deviation of the mean, and statistical significance was determined using a paired Student’s t-test at each time point, *p<0.05.

Figure 2. Chicken primary B cells can support the replication of both cell-culture adapted and very virulent strains of IBDV. Chicken primary B cells were mock-infected or infected with either D78 or UK661 and a sample from each culture was fixed, labelled and imaged: IBDV VP2, green; nuclei, blue; scale bar, 7µm (A). RNA was extracted at the indicated time-points post-infection, reverse transcribed and a conserved region of the IBDV VP4 gene was amplified by quantitative PCR (B). The log_{10} fold change in VP4 copy number was normalised to the TBP house-keeping gene and expressed relative to mock-infected samples as per the 2^{-ΔΔCT} method. Data shown are representative of at least three replicate experiments, and error bars represent the standard deviation of the mean.

Figure 3. The expression of IFNβ and IFIT5 is significantly up-regulated in chicken primary B cells infected with D78 compared to cells infected with UK661. RNA was extracted from mock-, D78- and UK661-infected cultures at the indicated time points post-infection, reverse transcribed and the chicken IFNβ (A) and IFIT5 (B) genes were amplified by quantitative PCR. The fold change in the expression of each gene was normalised and expressed relative to mock-infected samples as per the 2^{-ΔΔCT} method. Error bars represent the standard deviation of the mean and statistical significance of the difference in gene expression.
expression in D78-infected cultures compared to UK661-infected cultures was determined
by using a two-way ANOVA (*p<0.05, ***p<0.001, ****p <0.0001).

Figure 4. Chicken primary B cells infected with UK661 and D78 have a differential
gene expression profile by microarray. RNA was extracted from mock-, D78- and UK661-
infected cultures at 18 hours post-infection, and subject to microarray analysis. (A) Venn
diagram showing the overlap of differentially expressed genes by D78 and UK661 relative to
mock-infected cultures. (B) Hierarchical Clustering heat map of 73 transcripts that were
found to be significantly regulated in at least one of the study’s microarray gene expression
comparisons using Partek v6.6 software: D78 Vs Mock (blue), UK661 Vs Mock (orange) and
D78 Vs UK661 (gray). Each column represents a sample, and each row represents mRNA
quantification of the indicated transcript. The default settings of Euclidian dissimilarity were
used for each row (log₂ transformed and median centred transcripts). The colour
corresponds to expression intensity values as indicated by the vertical legend (red, up-
regulated; dark blue, down-regulated). (C) Distribution histogram of GO process term
enrichment analysis using the MetaCore enrichment analysis tool. The ten most enriched
GO process terms in the microarray comparisons D78 (blue) and UK661 (orange) were
plotted relative to mock, as sorted by "statistically significant maps," which list terms in
decreasing order of the standard deviation of the -log (p-Value) between the two
comparisons. (D) Comparison of the relative expression of known chicken ISGs between B
cells infected with D78 (blue) and UK661 (orange).

Figure 5. Validation of the microarray results by RTqPCR. The log₁₀ fold change of a
panel of innate immunity related genes (IFIT5, IFI6, OASL, Mx1, RSAD2, IFIH1, IFNα and
IFNβ) was determined by microarray and RTqPCR, and plotted against one another.
GraphPad Prism v7.0a was used to calculate the mean Spearman correlation coefficient (r).
Supplementary Figure 1. Four alternative views of three-dimensional scatter PCA plots displaying the similarity of expression of samples as indicated by dots. Bounding ellipses and colours represent mock- (red), D78- (blue) and UK661- (green) infected samples.

Supplementary Figure 2. Enrichment analysis of the genes identified in the microarray comparison D78 Vs Mock by MetaCore: (A) GO Processes, (B) Process networks. The p-value is estimated by MetaCore ‘Statistically significant’ method. MetaCore version 6.31 build 68930.

Supplementary Figure 3. Enrichment analysis of the genes identified in the microarray comparison UK661 Vs Mock by MetaCore: (A) GO Processes, (B) Processes networks. The p-value is estimated by MetaCore ‘Statistically significant’ method. MetaCore version 6.31 build 68930.

Supplementary Figure 4. Enrichment analysis of the genes identified in the microarray comparison D78 Vs UK661 by MetaCore: (A) GO Processes, (B) Process networks. The p-value is estimated by MetaCore ‘Statistically significant’ method. MetaCore version 6.31 build 68930.
Figure 1. Chicken primary B cells can be cultured in the presence of chicken CD40L.
Figure 2. Chicken primary B cells can support the replication of both cell-culture adapted and very virulent strains of IBDV
Figure 3. The expression of IFNβ and IFIT5 is significantly up-regulated in chicken primary B cells infected with D78 compared to cells infected with UK661.
Figure 4. Chicken primary B cells infected with UK661 and D78 have a differential gene expression profile by microarray.
Figure 5. Validation of the microarray results by RTqPCR.
A. GO Processes

1. defense response to virus
2. immune system process
3. immune effector process
4. regulation of defense response
5. innate immune response
6. defense response
7. response to virus
8. regulation of immune system process
9. regulation of immune response
10. defense response to other organism

B. GeneGO Process Networks

1. Inflammation_Interferon signaling
2. Immune response_Innate immune response to RNA viral infection
3. Inflammation_IFN-gamma signaling
4. Inflammation_Inflammasome
5. Immune response_T helper cell differentiation
6. Cell adhesion_Platelet-endothelium-leucocyte interactions
7. Inflammation_Innate inflammatory response
8. Blood coagulation
9. Inflammation_IL-4 signaling
10. Apoptosis_Apoptotic nucleus
Supplementary Figure 3

A. GO Processes

1. positive regulation of vascular endothelial growth factor signaling pathway
2. positive regulation of cell migration by vascular endothelial growth factor signaling pathway
3. regulation of vascular endothelial growth factor signaling pathway
4. regulation of cellular response to vascular endothelial growth factor stimulus
5. vascular endothelial growth factor signaling pathway
6. regulation of bicellular tight junction assembly
7. regulation of innate immune response
8. positive regulation of protein targeting to membrane
9. positive regulation of cellular response to insulin stimulus
10. regulation of protein targeting to membrane

B. GeneGO Process Networks

1. Immune response_Innate immune response to RNA viral infection
2. Inflammation_Interferon signaling
3. Proteolysis_Proteolysis in cell cycle and apoptosis
4. Transcription_Transcription by RNA polymerase II
5. Cytoskeleton_Actin filaments
6. Immune response_Phagocytosis
A. GO Processes

B. GeneGO Process Networks

Supplementary Figure 4
### Supplementary Table 1

**Primer and probe sequences used in quantitative PCR**

| Target | Forward primer (5'-3') | Reverse primer (5'-3') | SYBR green or Taqman | Taqman Probe (5'-3') |
|--------|------------------------|------------------------|----------------------|----------------------|
| VP4    | GAGGTGGGCGAGCTAACC    | GCCGATTATGTCTTTGAAG     | Taqman               | FAM-CCCCTGAAATGCAGGACATT-TAMRA |
| TBP    | CTTCTGCCCCAAATGCT     | GCGCAGTACGTCTGTTCTCTTT | Taqman               | FAM-CTCATAATAACGAGAAACGCTTGGGATTAMRA |
| GAPDH  | GGCACCTGCAAGGCTGAGAA  | TGCATGCGCCATTGATGT      | SYBR green           | N/A*                 |
| IFIT5  | TGCTTCACCAGCTGACTGCTGC| TGGGTTTGCTCTGCACTTTT    | SYBR green           | N/A                  |
| IFI6   | TGACCCAGAGTCCACAAGC   | ACCTGCTCTGGACGATGCTTT  | SYBR green           | N/A                  |
| OASL   | AAGAAGGATGGAGTGGTGGC  | CCTTACAGCTCCAGACTGTT    | SYBR green           | N/A                  |
| MX1    | CACACCACTGTCAGCGAT    | ATGTCGAAACTCTCTCGGG     | SYBR green           | N/A                  |
| RSAD2  | GACACAGAGGACAGAGATG   | TCCGCTACTTAAGCATTG      | SYBR green           | N/A                  |
| IFIH1  | AAGATGAAACAGAGGGCA    | CCACGCTCTGAGGAGACAGCA  | SYBR green           | N/A                  |
| IFNa   | CCACCGCTACACCAGACC    | ATGGTGAAGTGAGGGTTGCAG   | SYBR green           | N/A                  |
| IFNb   | CAGTCCAGGAGGATGACAG   | GAGAAGGTTGGTGAGAGC      | SYBR green           | N/A                  |

*N/A, not applicable*
### Supplementary Table 2. Microarray data, D78 Vs Mock

| Gene symbol | Gene title                                                                 | Refseq transcript ID                                                                 | FDR* value | Fold change |
|-------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------|------------|-------------|
| IFI6        | interferon, alpha-inducible protein 6                                     | NM_001001296                                                                         | 4.12E-06   | 57.9065     |
| OASL        | 2'-5'-oligoadenylate synthetase-like                                       | NM_205041                                                                             | 1.17E-08   | 19.1718     |
| USP18       | ubiquitin specific peptidase 18                                            | XM_004937958 /// XM_004937959 /// XM_416398                                           | 1.23E-08   | 16.7873     |
| CCL4 /// GGCL1 CCL4 /// CCL5 GGCL1 GGCL1 /// LOC770718 GGCL1 /// LOC770718 MX1 | chemokine (C-C motif) ligand 4 /// chemokine-like ligand 1                            | NM_001045831 /// NM_204720 NM_001030360 /// NM_001045832 NM_001045831 /// NM_001045831 /// | 9.24E-08   | 15.4576     |
| EPST1I      | epithelial stromal interaction 1 (breast)                                 | NM_001277666                                                                         | 1.97E-07   | 10.3651     |
| LOC100858381| chromosome 11 open reading frame, human C19orf12-like                     | XM_421662                                                                             | 4.23E-07   | 9.76258     |
| IFIT5       | interferon-induced protein with tetratricopeptide repeats 5               | XM_416896                                                                             | 6.10E-07   | 8.44307     |
| LOC418700   | lysozyme g-like                                                          | XM_426208                                                                             | 1.39E-05   | 8.21752     |
| RSAD2       | radical S-adenosyl methionine domain containing 2                          | XM_001193638                                                                          | 3.07E-06   | 7.13198     |
| IFIH1       | interferon induced with helicase C domain 1                              | XM_004941027 /// XM_420476                                                           | 5.58E-06   | 4.27848     |
| LOC422513   | hect domain and RLD 4-like                                               | XM_004939297 /// XM_004939298                                                         | 7.09E-06   | 4.27542     |
| SAMD9L      | sterile alpha motif domain containing 9-like                              | XM_004947072 /// XM_004947073 /// XM_004947074 /// XM_417395                           | 1.87E-07   | 4.10764     |
| ZNFX1       | zinc finger, NFX1-type containing 1                                      | XM_004947072 /// XM_004947073 /// XM_004947074 /// XM_417395                           | 1.11E-07   | 4.08068     |
| PLACL2      | Placenta-specific gene 8-like                                             | XM_00494122                                                                           | 9.89E-08   | 3.39104     |
| LOC420107   | paramyosin-like                                                          | XM_01277658                                                                           | 1.34E-05   | 3.35861     |
| LOC417192   | torsin family 1, member B-like                                           | XM_01277658                                                                           | 2.34E-05   | 3.24774     |
| IRF1        | interferon regulatory factor 1                                           | XM_005415                                                                             | 2.34E-05   | 3.24774     |
| LOC101750271| peroxisome proliferator-activated receptor gamma coactivator-related protein 1-like | XM_004939923 /// XM_004939924 /// XM_004939925 /// XM_004939926 /// XM_004939927  | 4.04E-06   | 3.17196     |
| MOV10       | Mov10, Moloney leukemia virus 10, homolog (mouse)                        | NM_001012843                                                                          | 8.63E-05   | 3.00717     |
| EIF2AK2     | eukaryotic translation initiation factor 2-alpha kinase 2                | NM_004847                                                                             | 2.82E-06   | 2.80896     |
| TRIM25      | tripartite motif containing 25                                           | XM_415653                                                                             | 1.22E-05   | 2.46013     |
| Gene Symbol | Description | Gene Accession Numbers | Fold Change | P-value |
|-------------|-------------|------------------------|-------------|---------|
| LOC770612   | interferon-induced transmembrane protein 1-like | XM_001233949 /// XM_004941314 | 5.31E-07 | 2.40368 |
| NMI         | N-myc (and STAT) interactor | XM_422160 | 1.46E-06 | 2.28534 |
| PARP14      | poly (ADP-ribose) polymerase family, member 14 | XM_422113 | 4.44E-07 | 2.18327 |
| PARP9       | poly (ADP-ribose) polymerase family, member 9 | XM_004942965 /// XR_212683 /// XR_212684 /// XR_212685 | 2.10E-06 | 2.16811 |
| IRF7        | interferon regulatory factor 7 | NM_205372 | 5.24E-06 | 2.13165 |
| HELZ2       | helicase with zinc finger 2, transcriptional coactivator | XM_004947281 /// XM_004947282 /// XM_004947283 /// XM_417438 | 5.31E-07 | 2.40368 |
| C15orf48    | chromosome 10 open reading frame, human C15orf48 | XM_413822 | 0.00017613 | 1.93654 |
| FOXS1 // IRF9 | forkhead box S1 // interferon regulatory factor 9 | NM_204558 /// XM_425714 | 4.47E-06 | 1.87349 |
| PHF11       | PHD finger protein 11 | XM_004938712 /// XM_417062 | 7.00E-06 | 1.83083 |
| PMAIP1      | phorbol-12-myristate-13-acetate-induced protein 1 | NM_001302097 /// XM_001233389 | 2.91E-06 | 1.82533 |
| SLBP        | stem-loop binding protein | NM_001004403 | 8.54E-06 | 1.7617 |
| LOC415756   | uncharacterized LOC415756 | NM_001277579 /// NM_001277581 /// NM_001277582 | 0.00025005 | 1.74594 |
| TFPI2       | tissue factor pathway inhibitor 2 | XM_418662 | 0.00033337 | 1.7295 |
| HMOX1       | heme oxygenase 1 | NM_205344 | 0.00010671 | 1.72761 |
| DHX58       | DEXH (Asp-Glu-X-His) box polypeptide 58 | XM_003642831 /// XM_004948614 /// XM_004948615 /// XM_004948616 | 0.00019504 | 1.71093 |
| SOCS1       | suppressor of cytokine signaling 1 | NM_001137648 | 5.87E-06 | 1.70385 |
| TGM2        | transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) | NM_205448 | 5.63E-05 | 1.70056 |
| IFI35       | interferon-induced protein 35 | XM_418132 | 7.03E-05 | 1.69867 |
| PXK         | PX domain containing serine/threonine kinase | XM_414403 | 5.62E-05 | 1.69538 |
| C1R         | complement component 1, r subcomponent | XM_416518 | 0.00019856 | 1.6751 |
| CCL4 /// GGCL1 CCL4 /// CCL5 CCL4 /// CCL5 CCL5 /// CCL5 CCL5 /// DDX60 | chemokine (C-C motif) ligand 4 /// chemokine-like ligand 1 | NM_001045831 /// NM_204720 NM_001030360 /// NM_001045832 NM_001030360 /// NM_001045832 | 6.82E-06 | 1.67195 |
| DDX60       | DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 | XM_003641151 /// XM_004940918 | 2.88E-05 | 1.6228 |
| LY96        | lymphocyte antigen 96 | XM_004939913 /// XM_418301 | 0.00022266 | 1.61474 |
| CMTR1       | cap methyltransferase 1 | XM_004935385 /// XM_419486 | 0.00021383 | 1.60165 |
| CD247       | CD247 molecule | NM_206879 | 2.82E-05 | 1.57437 |
| IFI27L2     | interferon, alpha-inducible protein 27-like 2 | NM_001002856 | 2.00E-05 | 1.56975 |
| Gene Symbol | Gene Name                                      | RefSeq Accession Numbers | FDR        | Log2 Ratio |
|-------------|-----------------------------------------------|--------------------------|------------|------------|
| CTSL2       | cathepsin L2                                  | NM_001168009              | 0.00015393 | 1.5651     |
| SNX10       | sorting nexin 10                              | NM_001030986              | 0.00020841 | 1.54188    |
| PML         | promyelocytic leukemia                        | XM_004943700 // XM_004943701 // XM_00493702 // XM_413690 | 2.93E-06   | 1.52237    |
| TRANK1      | tetra-tricopeptide repeat and ankyrin repeat containing 1 | XM_004939507 // XM_004939508 // XM_418827 | 0.0001907  | 1.51849    |
| DACT2       | dishevelled-binding antagonist of beta-catenin 2 | XM_419602                | 6.24E-08   | 1.50929    |
| UBE2E1      | ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) | XM_001235065 // XM_004939407 // XM_004939408 // XM_004939410 | 0.00036619 | -1.51358   |
| GRAP        | GRB2-related adaptor protein                   | NM_001277553              | 4.46E-07   | -1.54699   |
| DUSP14      | dual specificity phosphatase 14                | XM_421399                 | 8.60E-05   | -1.62136   |
| TLR1LA      | toll-like receptor 1-like A                   | NM_001007488              | 0.00024001 | -1.63588   |
| LOC426106   | C-type lectin domain family 17, member A-like | XM_423779                 | 1.11E-05   | -1.63925   |
| TDRP        | testis development related protein             | XM_419923                 | 0.00018644 | -1.75741   |
| PCMTD1      | protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 | NM_001031019              | 0.00020749 | -1.77333   |
| CD72        | CD72 molecule                                  | NM_205052                 | 3.38E-06   | -1.83223   |
| LOC396098   | B6.1                                          | NM_205182                 | 5.69E-07   | -1.97989   |
| MDK         | midkine (neurite growth-promoting factor 2)    | NM_001113289              | 0.00016347 | -2.38187   |
| F10         | coagulation factor X                           | NM_205022                 | 9.67E-05   | -2.40541   |
| PMP2        | peripheral myelin protein 2                    | NM_001199476              | 0.00028399 | -5.40443   |

*FDR, False Discovery Rate
**Supplementary Table 3. Microarray data, UK661 Vs Mock**

| Gene symbol | Gene title                                                  | Refseq transcript ID                          | FDR* value | Fold change |
|-------------|-------------------------------------------------------------|-----------------------------------------------|------------|-------------|
| EPSTI1      | epithelial stromal interaction 1 (breast)                   | XM_417033                                    | 2.41E-06   | 5.82867     |
| USP18       | ubiquitin specific peptidase 18                             | XM_004937958 /// XM_004937959 /// XM_416398  | 4.08E-07   | 4.798       |
| LOC100858381| chromosome 11 open reading frame, human C19orf12-like       | NM_001277666                                  | 3.34E-06   | 4.26295     |
| OASL        | 2'-5'-oligoadenylate synthetase-like                        | NM_205041                                    | 4.59E-06   | 2.95086     |
| MX1         | myxovirus (influenza virus) resistance 1, interferon-       | NM_204609                                    | 3.11E-05   | 2.61957     |
| ZNFX1       | zinc finger, NFX1-type containing 1                         | XM_004947072 /// XM_004947073 /// XM_417395  | 1.96E-06   | 2.58731     |
| PLACL2      | Placenta-specific gene 8-like 2                             | XM_003641174 /// XM_004941120 /// XM_004941121 /// XM_417395 | 5.40E-06 | 2.07364     |
| LOC770612   | interferon-induced transmembrane protein 1-like             | XM_001233949 /// XM_004941314                 | 5.98E-06   | 1.78927     |
| NMI         | N-myc (and STAT) interactor                                 | XM_422160                                    | 1.58E-05   | 1.73484     |
| LOC420107   | paramyosin-like                                             | XM_418228                                    | 1.06E-05   | 1.73994     |
| PARP9       | poly (ADP-ribose) polymerase family, member 9              | XM_004942965 /// XR_212683 /// XR_212684 /// XR_212685 | 3.59E-05 | 1.60953     |
| PARP14      | poly (ADP-ribose) polymerase family, member 14             | XM_422113                                    | 9.12E-06   | 1.59646     |

*FDR, False Discovery Rate*
**Supplementary Table 4. Microarray data, D78 Vs UK661**

| Gene symbol | Gene title                                                                 | Refseq transcript ID                                                                 | FDR* value   | Fold change |
|-------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------|-------------|
| CCL4 /// GGCL1 | chemokine (C-C motif) ligand 4 /// chemokine-like ligand 1 chemokine (C-C motif) ligand | NM_001045831 /// NM_204720 NM_001030360 /// NM_001045832 NM_001045831 NM_001045831 | 4.35E-07     | 8.2524      |
| RSAD2       | radical S-adenosyl methionine domain containing 2                           | XM_426208                                                                            | 1.47E-05     | 8.0404      |
| IFI6        | interferon, alpha-inducible protein 6                                       | NM_001001296                                                                         | 0.00215425   | 7.67472     |
| OASL        | 2'-5' oligoadenylate synthetase-like                                        | NM_205041                                                                            | 1.79E-07     | 6.49702     |
| MX1         | myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) | NM_204609                                                                            | 1.23E-06     | 5.32367     |
| IFIT5       | interferon-induced protein with tetratricopeptide repeats 5               | XM_421662                                                                            | 6.38E-06     | 4.21625     |
| LOC4187000  | lysozyme g-like                                                            | XM_416896                                                                            | 7.32E-06     | 4.05571     |
| USP18       | ubiquitin specific peptidase 18                                            | XM_004937958 // XM_004937959 // XM_416398                                            | 1.55E-06     | 3.49882     |
| LOC101750271| peroxisome proliferator-activated receptor gamma coactivator-related protein 1-like | XM_004939923 // XM_004939924 // XM_004939925 // XM_004939926 // XM_004939927 | 9.19E-06     | 2.72723     |
| LOC100858381| chromosome 11 open reading frame, human C19orf12-like                     | NM_001277666                                                                         | 5.74E-05     | 2.43143     |
| SAMD9L      | sterile alpha motif domain containing 9-like                               | XM_004939297 // XM_004939298                                                         | 0.00185293   | 2.27562     |
| LOC420107   | paramyosin-like                                                            | XM_418228                                                                            | 3.56E-06     | 1.94894     |
| HBG2        | hemoglobin, gamma G                                                        | NM_205489                                                                            | 0.000285478  | 1.88629     |
| EIF2AK2     | eukaryotic translation initiation factor 2-alpha kinase 2                  | NM_204487                                                                            | 6.44E-05     | 1.8271      |
| TGM2        | transglutaminase 2 (C polypeptide, protein-glutamine-                        | NM_205448                                                                            | 3.63E-05     | 1.77399     |
| Gene Symbol | Description                                           | Accession Numbers | Fold Change | False Discovery Rate |
|-------------|-------------------------------------------------------|-------------------|-------------|----------------------|
| TFPI2       | tissue factor pathway inhibitor 2                     | XM_418662         | 0.000285737 | 1.75674              |
| HELZ2       | helicase with zinc finger 2, transcriptional coactivator | XM_004947281 /// XM_004947282 /// XM_004947283 /// XM_417438 | 2.95E-05 | 1.69622              |
| HSP25       | heat shock protein 25                                 | NM_001010842      | 0.000120417 | 1.62094              |
| PMAIP1      | phorbol-12-myristate-13-acetate-induced protein 1     | NM_001302097 /// XM_001233389 | 0.00011368 | 1.60593              |
| CCL4 /// CCL5 | chemokine (C-C motif) ligand 4 /// chemokine-like ligand 1 | NM_001045831 /// NM_204720 NM_001030360 /// NM_001045832 | 1.11E-05 | 1.60468              |
| HSP25       | heat shock protein 25                                 | NM_001010842      | 0.000120417 | 1.62094              |
| PMAIP1      | phorbol-12-myristate-13-acetate-induced protein 1     | NM_001302097 /// XM_001233389 | 0.00011368 | 1.60593              |
| CCL4 /// CCL5 | chemokine (C-C motif) ligand 4 /// chemokine-like ligand 1 | NM_001045831 /// NM_204720 NM_001030360 /// NM_001045832 | 1.11E-05 | 1.60468              |
| PXK         | PX domain containing serine/threonine kinase         | XM_414403         | 0.000105587 | 1.60379              |
| HMOX1       | heme oxygenase 1                                      | NM_205344         | 0.000257544 | 1.59495              |
| ZNFX1       | zinc finger, NFX1-type containing 1                   | XM_004947072 /// XM_004947073 /// XM_004947074 /// XM_417395 | 0.000127532 | 1.58761              |
| SLBP        | stem-loop binding protein                             | NM_001004403      | 2.94E-05    | 1.58044              |
| DDX60       | DEAD (Asp-Glu-Ala-Asp) box polypeptide 60             | XM_003641151 /// XM_004940918 | 4.42E-05 | 1.56746              |
| CD72        | CD72 molecule                                         | NM_205052         | 2.61E-05    | -1.53195             |
| TNFSF13B    | tumor necrosis factor (ligand) superfamily, member 13b | NM_204327         | 0.000194622 | -1.53242             |
| LOC422305   | ES1 protein homolog, mitochondrial-like                | XM_004940766 /// XM_420282 | 4.41E-08 | -1.55093             |
| MCOLN2      | mucolipin 2                                           | XM_004936646 /// XM_422368 | 0.000211533 | -1.58446             |
| TLR1LA      | toll-like receptor 1-like A                           | NM_001007488      | 0.000188778 | -1.67192             |
| UBE2E1      | ubiquitin-conjugating enzyme E2E 1 (UBC4/S homolog, yeast) | XM_001235065 /// XM_004939407 /// XM_004939408 /// XM_004939409 /// XM_004939410 | 7.45E-05 | -1.73589             |
| LOC396098   | B6.1                                                  | NM_205182         | 1.79E-06    | -1.75579             |
| PLD4        | phospholipase D family, member 4                      | XM_421399         | 3.60E-05    | -1.75597             |
| F10         | coagulation factor X                                  | NM_205022         | 0.000259184 | -2.08685             |
| PMP2        | peripheral myelin protein 2                           | NM_001199476      | 0.000269532 | -5.49215             |

*FDR, False Discovery Rate*